Core Insights - Obagi Medical has selected Platinum Dermatology Partners as the first partner for its ALOHA Program, emphasizing a commitment to clinical evidence and practice dissemination [1][5] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare and aesthetic solutions, part of Waldencast plc, with over 35 years of experience in advanced skincare [6] - Platinum Dermatology Partners operates over 120 locations with nearly 400 providers across multiple states, focusing on exceptional dermatology practices [7] - Waldencast plc aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to generate real-world data to translate clinical safety and efficacy from FDA trials into everyday practice [2] - The ALOHA Real-World Program will provide hands-on experience with Obagi saypha MagIQ, enhancing patient satisfaction and provider relationships [3] - Initial findings from the program will be presented at the annual Platinum Summit and key industry conferences to showcase the product's real-world impact [4] Product Information - Obagi saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed for natural-looking results and high performance [5]

Core Insights - Onco-Innovations Limited's subsidiary, Inka Health Corp., has published a technical primer on the transportability of real-world evidence (RWE) [1] - The primer addresses the challenge of adapting medical evidence from one country for use in another, which is crucial for global healthcare decision-making [1] - The publication is co-authored with experts from AstraZeneca Canada, highlighting collaboration in addressing healthcare assessment challenges [1] Company Developments - Inka Health Corp. has released a technical primer in the Journal of Clinical Evaluative Research (JCER) [1] - The focus of the primer is on advanced statistical transportability methods [1] - The publication aims to enhance the relevance of non-local RWE in health technology assessment [1]